(TheNewswire)
Toronto, Canada / TheNewswire / January 10, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce the appointment of David McPhedran as Director of Sales for North America, effective immediately.
"I am excited to welcome Dave to the Ventripoint team,” stated Desmond Hirson, President of Ventripoint. "He has a successful track record in establishing and managing sales teams for imaging products in the North American marketplace."
"I am honored and excited to join the Ventripoint team," said David McPhedran. "Ventripoint is an impressive company with innovative products to improve patient cardiac diagnosis and care. I have engaged numerous cardiologists across Canada and can report that they are very interested in Ventripoint’s technology as it helps to address the need for affordable, accurate cardiac measurement tools.”
Dave McPhedran is an experienced leader in the healthcare industry. Previously, he was Director of Sales for imaging in Western Canada for Siemens Healthcare, where his team achieved sales targets of $35M per year. Dave has also worked for Becton Dickinson and Johnson & Johnson in sales and marketing. He received his Bachelor of Science degree from the University of Waterloo.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Corporation has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information, contact:
Dr. George Adams, CEO
T: 519-803-6937
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Copyright (c) 2018 TheNewswire - All rights reserved.
